Strategic partnerships Matinas BioPharma collaborates with leading pharmaceutical companies to develop novel formulations leveraging its lipid nanocrystal (LNC) platform, presenting a clear opportunity to propose co-development or licensing arrangements that expand the use of LNC beyond internal programs.

Intracellular delivery focus The LNC platform targets intracellular delivery for small molecules and larger payloads (mRNA, DNA, antisense, vaccines), suggesting sales potential in contract development for specialized intracellular delivery challenges that current delivery methods struggle with.

Clinical and preclinical assets With a portfolio spanning preclinical and clinical data and ongoing development such as MAT2203 for oral antifungal therapy, there is a upsell opportunity to partners seeking new administration routes or broad-spectrum oral agents.

Financial headroom and risk Recent strategic reductions and cash conservation signals potential openness to cost-efficient collaboration models, such as milestone-based licensing or grant-supported programs, aligning with buyers seeking risk-adjusted partnerships.

Board and leadership dynamism New independent directors and an emphasis on governance indicate a company in a growth-transformation phase, making it a favorable target for early BD outreach around strategic alliances, joint ventures, or technology licensing.